Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Current Leases (2019 - 2025)

VYNE Therapeutics (VYNE) has disclosed Current Leases for 7 consecutive years, with $25000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Current Leases fell 79.17% year-over-year to $25000.0, compared with a TTM value of $25000.0 through Jun 2025, down 79.17%, and an annual FY2024 reading of $99000.0, down 13.91% over the prior year.
  • Current Leases was $25000.0 for Q2 2025 at VYNE Therapeutics, down from $63000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $647000.0 in Q1 2021 and bottomed at $25000.0 in Q2 2025.
  • Average Current Leases over 5 years is $192307.7, with a median of $117000.0 recorded in 2024.
  • The sharpest move saw Current Leases plummeted 92.86% in 2022, then decreased 13.91% in 2024.
  • Year by year, Current Leases stood at $349000.0 in 2021, then crashed by 91.12% to $31000.0 in 2022, then surged by 270.97% to $115000.0 in 2023, then decreased by 13.91% to $99000.0 in 2024, then crashed by 74.75% to $25000.0 in 2025.
  • Business Quant data shows Current Leases for VYNE at $25000.0 in Q2 2025, $63000.0 in Q1 2025, and $99000.0 in Q4 2024.